Abstract: The present invention provides a method for determining the degree of macrophage-associated negative effects on a vertebrate including a human, the method including assaying diacetylpolyamine contained in a sample collected from the vertebrate. According to the method of the present invention, metabolic conditions of macrophages can be monitored, and the degree of macrophage-associated negative effects on a vertebrate (including a human) can be determined. Specifically, the present invention can predict, through assay of diacetylpolyamine, pathological condition which is considered a macrophage-related disease; e.g., recurrence of cancer or malignant tumor, or infiltration or activation of cancer or malignant tumor cells; denaturation or degeneration of neurons associated with Alzheimer's disease; or onset or progression of an autoimmune disease (e.g., rheumatism or Crohn's disease) or arteriosclerosis. Therefore, the present invention is very useful for clinical tests.

Abstract: A method for determining hydrolase activity of carbonic anhydrase I (CAI) in a sample which employs, combination of a substrate and an inhibitor. The substrate is a substrate having higher reactivity with CAI than with CAII selected from 2-hydroxy-5-nitro-?-toluenesulfonic acid sultone, a o-nitrophenyl ester, a p-nitropheylthio ester, and a ?-naphthyl ester or a substrate having reactivity with both CAI and CAII selected from the group consisting of a p-nitrophenyl ester and a ?-naphthyl ester. The substrate having higher reactivity with CAI than with CAII is a substrate that reacts with CAI in an amount, per amount of enzyme protein, twice or more the amount of substrate reacting with CAII, under identical substrate concentrations and reaction times and that specifically binds to CAI and serves as a substrate for hydrolase activity. The inhibitor is an inhibitor inhibiting a hydrolase other than CA, a CA inhibitor inhibiting both CAI and CAII, or a CA inhibitor inhibiting CAI more potently than CAII.

Abstract: The present invention relates to a method for long-term stabilizing a pulmonary surfactant protein, to a stabilized aqueous solution containing a pulmonary surfactant protein, and to a kit for assaying a pulmonary surfactant protein which kit contains, as a component reagent, a stabilized aqueous solution containing a pulmonary surfactant protein. The invention provides a method for stabilizing a pulmonary surfactant protein, the method including causing the pulmonary surfactant protein to be present with a calcium ion and an oxidizing/reducing substance. The invention also provides an aqueous solution containing a pulmonary surfactant protein which has been stabilized by use of a calcium ion and an oxidizing/reducing substance in combination.

Abstract: The present invention provides a method for determining the degree of macrophage-associated negative effects on a vertebrate including a human, the method including assaying diacetylpolyamine contained in a sample collected from the vertebrate. According to the method of the present invention, metabolic conditions of macrophages can be monitored, and the degree of macrophage-associated negative effects on a vertebrate (including a human) can be determined. Specifically, the present invention can predict, through assay of diacetylpolyamine, pathological condition which is considered a macrophage-related disease; e.g., recurrence of cancer or malignant tumor, or infiltration or activation of cancer or malignant tumor cells; denaturation or degeneration of neurons associated with Alzheimer's disease; or onset or progression of an autoimmune disease (e.g., rheumatism or Crohn's disease) or arteriosclerosis. Therefore, the present invention is very useful for clinical tests.

Abstract: The present invention provides a method for determining the degree of macrophage-associated negative effects on a vertebrate including a human, the method including assaying diacetylpolyamine contained in a sample collected from the vertebrate. According to the method of the present invention, metabolic conditions of macrophages can be monitored, and the degree of macrophage-associated negative effects on a vertebrate (including a human) can be determined. Specifically, the present invention can predict, through assay of diacetylpolyamine, pathological condition which is considered a macrophage-related disease; e.g., recurrence of cancer or malignant tumor, or infiltration or activation of cancer or malignant tumor cells; denaturation or degeneration of neurons associated with Alzheimer's disease; or onset or progression of an autoimmune disease (e.g., rheumatism or Crohn's disease) or arteriosclerosis. Therefore, the present invention is very useful for clinical tests.

Abstract: The present invention provides a method for preventing degradation of diacetylpolyamine in a solution containing diacetylpolyamine, the method including adding a proteinase inhibitor and/or a peptidase inhibitor to the solution, or lowering the pH of the solution. Employment of the method of the present invention realizes inhibition of degradation of diacetylpolyamine in a solution containing diacetylpolyamine, and determination of more accurate assay data on diacetylpolyamine. The method of the present invention is widely applicable to, for example, a sample containing proteinase or peptidase (e.g., urine or cell lysate), or an assay reaction mixture which may unintentionally contain proteinase or peptidase. Therefore, the method is very useful for assay of diacetylpolyamine.

Abstract: The present invention relates to a method for long-term stabilizing a pulmonary surfactant protein, to a stabilized aqueous solution containing a pulmonary surfactant protein, and to a kit for assaying a pulmonary surfactant protein which kit contains, as a component reagent, a stabilized aqueous solution containing a pulmonary surfactant protein. The invention provides a method for stabilizing a pulmonary surfactant protein, the method including causing the pulmonary surfactant protein to be present with a calcium ion and an oxidizing/reducing substance. The invention also provides an aqueous solution containing a pulmonary surfactant protein which has been stabilized by use of a calcium ion and an oxidizing/reducing substance in combination.

Abstract: The present invention provides a method for determining the degree of macrophage-associated negative effects on a vertebrate including a human, the method including assaying diacetylpolyamine contained in a sample collected from the vertebrate. According to the method of the present invention, metabolic conditions of macrophages can be monitored, and the degree of macrophage-associated negative effects on a vertebrate (including a human) can be determined. Specifically, the present invention can predict, through assay of diacetylpolyamine, pathological condition which is considered a macrophage-related disease; e.g., recurrence of cancer or malignant tumor, or infiltration or activation of cancer or malignant tumor cells; denaturation or degeneration of neurons associated with Alzheimer's disease; or onset or progression of an autoimmune disease (e.g., rheumatism or Crohn's disease) or arteriosclerosis. Therefore, the present invention is very useful for clinical tests.

Abstract: To provide a method for specifically determining CA isozyme activity. The method for determining hydrolase activity of carbonic anhydrase I (CAI) in a sample, which is characterized in that the method employs, as a substrate or a combination of a substrate and an inhibitor, any of the following (A) to (E): (A) Substrate: a substrate having higher reactivity with CAI than with CAII; (B) Substrate: a substrate having higher reactivity with CAI than with CAII; Inhibitor: an inhibitor inhibiting a hydrolase other than CA, and an optional drug for enhancing inhibitory activity of the inhibitor; (C) Substrate: a substrate having higher reactivity with CAI than with CAII, and Inhibitor: a CA inhibitor inhibiting both CAI and CAII; (D) Substrate: a substrate having reactivity with both CAI and CAII, and Inhibitor: a CA inhibitor inhibiting CAI more potently than CAII; and (E) Substrate: a substrate having higher reactivity with CAI than with CAII, and Inhibitor: a CA inhibitor inhibiting CAI more potently than CAII.